- Home
- PROV vs COEP Comparison
PROV vs COEP Comparison
Compare PROV & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROV
- COEP
- Stock Information
- Founded
- PROV 1956
- COEP 2017
- Country
- PROV United States
- COEP United States
- Employees
- PROV N/A
- COEP N/A
- Industry
- PROV Savings Institutions
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PROV Finance
- COEP Health Care
- Exchange
- PROV Nasdaq
- COEP Nasdaq
- Market Cap
- PROV 103.5M
- COEP 86.0M
- IPO Year
- PROV 1996
- COEP N/A
- Fundamental
- Price
- PROV $15.69
- COEP $14.96
- Analyst Decision
- PROV Hold
- COEP
- Analyst Count
- PROV 1
- COEP 0
- Target Price
- PROV $16.50
- COEP N/A
- AVG Volume (30 Days)
- PROV 7.9K
- COEP 39.8K
- Earning Date
- PROV 10-28-2025
- COEP 11-10-2025
- Dividend Yield
- PROV 3.55%
- COEP N/A
- EPS Growth
- PROV N/A
- COEP N/A
- EPS
- PROV 0.90
- COEP N/A
- Revenue
- PROV $39,823,000.00
- COEP $263,555.00
- Revenue This Year
- PROV $7.74
- COEP N/A
- Revenue Next Year
- PROV $4.06
- COEP N/A
- P/E Ratio
- PROV $17.55
- COEP N/A
- Revenue Growth
- PROV 0.07
- COEP N/A
- 52 Week Low
- PROV $12.98
- COEP $2.31
- 52 Week High
- PROV $16.70
- COEP $19.19
- Technical
- Relative Strength Index (RSI)
- PROV 48.99
- COEP 47.93
- Support Level
- PROV $15.60
- COEP $14.68
- Resistance Level
- PROV $15.98
- COEP $16.45
- Average True Range (ATR)
- PROV 0.19
- COEP 0.83
- MACD
- PROV -0.02
- COEP -0.17
- Stochastic Oscillator
- PROV 40.92
- COEP 15.42
About PROV Provident Financial Holdings Inc.
Provident Financial Holdings Inc is a holding company of Provident Savings Bank, F.S.B. It is a financial services company committed to serving consumers and small to mid-sized businesses in the Inland Empire region of Southern California. Its business activities consist of community banking, investment services and trustee services for real estate transactions. The group operates in Bank segment that include attracting deposits, offering banking services and originating and purchasing single-family, multi-family, commercial real estate, construction and, to a lesser extent, other mortgage, commercial business and consumer loans. Its evenues are derived from interest earned on its loan and investment portfolios, and fees generated through its community banking activities.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.